Managing hyperparathyroidism in hemodialysis: role of etelcalcetide

Secondary hyperparathyroidism (SHPT) is common in patients receiving maintenance hemodialysis and is associated with adverse outcomes. Currently, SHPT is managed by reducing circulating levels of phosphate with oral binders and parathyroid hormone (PTH) with vitamin D analogs and/or the calcimimetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Eidman, Keith E, Wetmore, James B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804266/
https://www.ncbi.nlm.nih.gov/pubmed/29440923
http://dx.doi.org/10.2147/IJNRD.S128252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804266/
https://www.ncbi.nlm.nih.gov/pubmed/29440923
http://dx.doi.org/10.2147/IJNRD.S128252

Ejemplares similares